Free Trial
NASDAQ:SNSE

Sensei Biotherapeutics Q1 2025 Earnings Report

Sensei Biotherapeutics logo
$0.36 -0.02 (-4.41%)
As of 05/9/2025 04:00 PM Eastern

Sensei Biotherapeutics EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.21
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Sensei Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sensei Biotherapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
7:00AM ET

Sensei Biotherapeutics Earnings Headlines

This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
Sensei Rockets on FY ’24 Results
Sensei Rockets on FY ’24 Results
See More Sensei Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email.

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:SNSE), an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

View Sensei Biotherapeutics Profile

More Earnings Resources from MarketBeat